Goldman Sachs

Eli Lilly and Novo Nordisk face new competition in slimming drugs market

The duopoly of US pharmaceuticals firm Eli Lilly and Danish Novo Nordisk in the slimming drugs market is threatened. 

Two firms, Viking Therapeutics and Roche, announced the development of three products and Viking's shot up 39% in one day. 

Goldman Sachs estimates the market for such drugs will grow from €14 billion to €130 billion by 2030.

Issue of new 30-year bond

Armed by the surprise move from Standard & Poor's last Friday, upgrading Greece's outlook to "Positive," the Public Debt Management Agency is on Wednesday set to make its second major market foray for 2024, with a new 30-year bond.

Int’l banks do not expect change in economic policies

In their assessments on the outcome of the March 31 local elections, Deutsche Bank and Goldman Sachs argued that the government is unlikely to change its economic policies.

Deutsche Bank in a report on April 1 that it is constructive on Turkish assets following the results of the March 31 elections.

Central Bank net reserves may turn positive: Goldman Sachs

The Turkish Central Bank's net reserves are likely to turn positive in 2024, according to analysts at Goldman Sachs.

In a note on the Central Bank's latest rate decision, Goldman Sachs said that it expects rising foreign inflows and a narrower current account deficit to pull the rate of Turkish Lira appreciation further inside the forwards in 2024.

Goldman Sachs anticipates more takings for Greek banks

Goldman Sachs expects Greek banks to show strong results in the third quarter of the year as well, following the trend of the second quarter, with further strengthening of net interest income, which will be supported by the 50-basis point increase in interest rates, to which it is estimated that the European Central Bank will have progressed in the specific period.

Pages